Organon
Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions. With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.
DitchCarbon Score
How does Organon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organon's score of 22 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Organon's reported carbon emissions
In 2023, Organon reported significant carbon emissions from its operations in the UK, with Scope 1 emissions reaching approximately 2,272,000,000 kg CO2e and Scope 2 emissions at about 5,557,000,000 kg CO2e. Additionally, Scope 3 emissions were substantial, including business travel (approximately 415,000,000 kg CO2e), employee commute (around 830,000,000 kg CO2e), and downstream transportation and distribution (approximately 920,000,000 kg CO2e). In 2022, the company recorded Scope 1 emissions of about 1,122,000,000,000 kg CO2e and Scope 2 emissions of approximately 5,677,000,000,000 kg CO2e in the UK, alongside significant Scope 3 emissions. The total emissions for 2021 globally were approximately 57,899,000 kg CO2e, with Scope 1 emissions at about 32,014,000 kg CO2e and Scope 2 emissions at around 32,918,000 kg CO2e. Despite these figures, Organon has not publicly committed to specific reduction targets or initiatives, indicating a lack of formalised climate pledges or science-based targets. The company operates within a challenging industry context, where substantial emissions are common, yet it has the opportunity to enhance its sustainability efforts moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 32,908,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Organon is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
